Dexrazoxane vs no cardioprotective intervention or placebo
Heart failure · adults with cancer receiving anthracyclines
Dexrazoxane probably leads to lower clinical heart failure Available case analysis compared with no cardioprotective intervention or placebo (moderate certainty).
1 finding from 1 review
- Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines 2022 · Cochrane Headline outcomes onlyRR 0.22 [0.11, 0.43]7 studies · 1221 participantsModerate